Literature DB >> 12027832

Olanzapine in Huntington's disease.

D Paleacu1, M Anca, N Giladi.   

Abstract

OBJECTIVES: To study the effect of olanzapine (OL) in Huntington's disease (HD) patients. DESIGN AND METHODS: Eleven HD patients (five men), aged 47.6 +/- 11.4 years and with disease duration of 11.2 +/- 3.3 years received OL. Assessment was carried out using the Clinical Global Impression of Change Scale (CGIC) and the Unified Huntington's Disease Rating Scale behavioral (UHDRS - b) and motor (UHDRS - m) at 6 month intervals.
RESULTS: Nine patients were treated for 9.8 +/- 5.9 months. The mean OL dose/patient was 11.4 +/- 8.5 mg/day (median 10 mg/day). Mean CGIC was 2.1 +/- 0.8. UHDRS - b improved significantly (P < 0.0001) and UHDRS - m did not change. Chorea improved in five patients and two dropped out because of drug eruption and lack of efficacy.
CONCLUSION: OL is a good alternative treatment in HD, mainly for the psychiatric symptoms and moderately effective for the motor symptoms, possibly because of its effect on chorea. We suggest OL should be used in HD patients with the adult onset form, severe chorea and/or severe psychiatric disturbances.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027832     DOI: 10.1034/j.1600-0404.2002.01197.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  22 in total

1.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Drug repositioning by integrating target information through a heterogeneous network model.

Authors:  Wenhui Wang; Sen Yang; Xiang Zhang; Jing Li
Journal:  Bioinformatics       Date:  2014-06-27       Impact factor: 6.937

Review 3.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 4.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

5.  Irritability in pre-clinical Huntington's disease.

Authors:  Stefan Klöppel; Cynthia M Stonnington; Predrag Petrovic; Dean Mobbs; Oliver Tüscher; David Craufurd; Sarah J Tabrizi; Richard S J Frackowiak
Journal:  Neuropsychologia       Date:  2009-10-28       Impact factor: 3.139

Review 6.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

Review 8.  An Update on the Treatment of Chorea.

Authors:  Erin Feinstein; Ruth Walker
Journal:  Curr Treat Options Neurol       Date:  2018-09-25       Impact factor: 3.598

Review 9.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

10.  Treatment of Irritability in Huntington's Disease.

Authors:  Erik van Duijn
Journal:  Curr Treat Options Neurol       Date:  2010-07-10       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.